Skip to main content
. 2017 Oct 24;89(17):1811–1820. doi: 10.1212/WNL.0000000000004570

Figure 2. Mean change in efficacy measures.

Figure 2

(A) Mean change from baseline to week 48 in 6MWD. (B) Mean change from baseline to week 48 in NSAA (linearized score on scale of 0–100). (C) Mean 6MWD (meters), baseline to week 48. (D) Mean percent of predicted 6MWD, baseline to week 48. *Primary efficacy endpoint. Analyses for each efficacy parameter included all patients with nonmissing baseline and at least 1 nonmissing postbaseline value (for 6MWD: n = 113 in placebo, 101 in tadalafil 0.3 mg/kg, and 111 for tadalafil 0.6 mg/kg; for NSAA: n = 116 in placebo, 102 in tadalafil 0.3 mg/kg, and 112 for tadalafil 0.6 mg/kg). LS = least squares; NSAA = North Star Ambulatory Assessment; 6MWD = 6-minute walk distance.